- life sciences/pharma sector
-
8th Annual Commercial Translation of Regenerative Medicine
Optimise cell product quality and overcome regulatory, reimbursement and funding challenges within successful clinical trials
Event Date: 18-19 Nov 2010
Location: Venue to be confirmed, London, United Kingdom
- key conference speakers
-
Geoff MacKay President and Chief Executive Officer, Organogenesis Gil Beyen Chief Executive Officer, Tigenix Yosuke Ozawa President and CEO, Japan Tissue Engineering Co. Ltd (J-TEC) Dr. William Haseltine Chairman, Haseltine Global Health LLC Dean Tozer Senior Vice President, Advanced BioHealing
- key conference topics
-
- Organogenesis addresses the issue of large scale manufacturing and distribution - maintaining quality and quantity
- Advanced BioHealing provides insight into achieving product regulatory approval and reimbursement success
- Tigenix presents the latest orthopaedic models used successfully in clinic with regulatory and reimbursement approval
- Japan Tissue Engineering Co. Ltd reviews the issues in commercialising regenerative medicine in Japan and conditions for approval and reimbursement
- Genzyme examines incorporating the concepts of pharmaceutical quality systems into regenerative medicine products
- conference focus
-
Regenerative Medicine has become the most lucrative area of modern day medicine with an estimated global market value of $500 Regenerative Medicine has become the most lucrative area of modern day medicine with an estimated global market value of $500 billion (US Department of Health). It offers companies the potential for substantial growth but to accomplish this requires major funding, research and quality control for translation to the bedside. By understanding how to overcome these challenges and achieve regulatory approval, a company can accelerate its rate of progress and attain unprecedented success.
This 8th annual marcus evans conference provides invaluable knowledge to develop business strategies to accomodate global pricing and reimbursement challenges and attract funding. Attendees will receive key industry and regulatory insight into improving cell product quality and evaluate the best methods available for cell delivery. This in turn will identify the link to translate your product from research phase into commercial clinical use, developing funding opportunities to excel in this breakthrough market.